Cargando…
Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
Among the pharmaceutical options available for treatment of ovarian cancer, increasing attention has been progressively focused on pegylated liposomal doxorubicin (PLD), whose unique formulation prolongs the persistence of the drug in the circulation and potentiates intratumor accumulation. Pegylate...
Autores principales: | Pisano, Carmela, Cecere, Sabrina Chiara, Di Napoli, Marilena, Cavaliere, Carla, Tambaro, Rosa, Facchini, Gaetano, Scaffa, Cono, Losito, Simona, Pizzolorusso, Antonio, Pignata, Sandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612436/ https://www.ncbi.nlm.nih.gov/pubmed/23577259 http://dx.doi.org/10.1155/2013/898146 |
Ejemplares similares
-
Ovarian cancer standard of care: are there real alternatives?
por: Pepa, Chiara Della, et al.
Publicado: (2015) -
Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006) -
Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009) -
The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer
por: Passarelli, Anna, et al.
Publicado: (2023) -
Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)